Alpha 2.0
Login Register
» Articles » PMID: 35064072

Double Bad Luck: Should Rare Diseases Get Special Treatment?

Overview
Journal J Med Ethics
Publisher BMJ Publishing Group
Specialty Medical Ethics
Date 2022 Jan 22
PMID 35064072
Authors
Adam Hutchings
Affiliations
Soon will be listed here.
Citing Articles

How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?.

Drummond M, Ciani O, Fornaro G, Jommi C, Dietrich E, Espin J BMC Health Serv Res. 2023; 23(1):484.

PMID: 37179322 PMC: 10182681. DOI: 10.1186/s12913-023-09494-5.

The ethics of aggregation in cost-effectiveness analysis or, "on books, bookshelves, and budget impact".

Charlton V Front Health Serv. 2023; 2:889423.

PMID: 36925796 PMC: 10012697. DOI: 10.3389/frhs.2022.889423.

HTA decision-making for drugs for rare diseases: comparison of processes across countries.

Stafinski T, Glennie J, Young A, Menon D Orphanet J Rare Dis. 2022; 17(1):258.

PMID: 35804398 PMC: 9264608. DOI: 10.1186/s13023-022-02397-4.